Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
David Cella(Northwestern University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Kristine Broglio(Berry & Associates (United States)), Homa Dastani(Bristol-Myers Squibb (United States)), Bryan Bennett(Adelphi Group (United Kingdom)), Elmer Berghorn(Bristol-Myers Squibb (United States)), Paul Nathan(Mount Vernon Hospital), Fiona Taylor(Adelphi Laboratory Center), Michael DeRosa(Adelphi Laboratory Center), Viktor Grünwald(Deutsche Schmerzgesellschaft), Justin Doan(Bristol-Myers Squibb (United States)), Scott Berry(Queen's University)
Cited by 219
Related Papers
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
|Journal of Clinical Epidemiology|2010|5.1k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Statins for the primary prevention of cardiovascular disease
|Cochrane Database of Systematic Reviews|2013|1.8k